Dynavax to Present at Upcoming Investor Conferences

PR Newswire

EMERYVILLE, Calif., May 28, 2024

EMERYVILLE, Calif.  , May 28, 2024 /PRNewswire/ --  Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:

• William Blair 44 ^th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT
• Goldman Sachs 45 ^th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations .

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn  and Twitter .

For Investors/Media:
Paul Cox
pcox@dynavax.com  
510-665-0499

Nicole Arndt
narndt@dynavax.com ,  510-665-7264

View original content to download multimedia: https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investor-conferences-302157153.html

SOURCE Dynavax Technologies